Victoria Bae-Jump, MD
Gynecologic Oncology · Chapel Hill, NCNPI 1295944114
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,301 of the $19,463 with a category attached, or 94.0%. Eisai Inc. accounts for 97.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $10,386 and has fallen 98.9% since, to $111 in 2025.
Across 19 payments — averaging $1024.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$19K
- Tesaro, Inc.$400
- GSK$175
Across 8 payments — averaging $96,420 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$771K
What the payments were for
- Consulting fees$18,30194%
- Travel & lodging$8194%
- Food & beverage$2781%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 16 | $18,888 |
| Tesaro, Inc. | 1 | $400 |
| GSK | 2 | $175 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,463 in reported general payments places this provider in the 80th percentile of 52 gynecologic oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 12 | $93,681 |
| PremarinEstrogens, Conjugated | 13 | $2,443 |
| Dexamethasone Sodium Phosphate | 17 | $608 |
| Gabapentin | 17 | $297 |
| Magnesium Sulfate | 14 | $235 |
| Prochlorperazine Maleate | 17 | $198 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Chapel Hill
- Stuart-Allison StaleyChapel Hill$3K
- Olivia LaraChapel Hill$3K
- Meredith NewtonChapel Hill$1K
- Glenn BoylesChapel Hill$1K
- Catherine JohnChapel Hill$1K
- Benjamin AlbrightChapel Hill$1K
- Leslie ClarkChapel Hill$543
- Linda van leChapel Hill$533
- Wesley FowlerChapel Hill$354
- John BoggessChapel Hill$80
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.